KeyBanc cuts NeuroPace stock price target on lowered estimates

KeyBanc reduced its price target on NeuroPace (NPCE) to $14 from $18, citing lower growth estimates after Q3 2026 revenue fell short. The company expects 5% growth in Q4 2026 and 15% in 2027. NPCE shares are down 22% YTD, trading at $12.02. KeyBanc maintains an Overweight rating, noting potential upside despite near-term challenges.

Original reporting
Published Nov 13, 2026, 10:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NPCE
Bearish
medium confidence
Mentioned
$NPCE
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NPCEBearishMed
01

Why it matters

Guidance cut and revenue miss drive negative sentiment; however, management cites future product growth.

02

Market read

The downgrade adds to bearish pressure on NPCE, a small‑cap biotech, with limited broader market effect.

03

What to watch

Potential upside from upcoming RNS product growth and 2027 outlook could offset short‑term weakness.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

NPCE develops neurostimulation devices; the company reported Q3 2026 revenue of $23.1M versus $27.1M expected.

Company-level read

Ticker impact

$NPCEBearishMedium confidence
Context

KeyBanc cut NPCE's price target to $14 from $18 after reporting a Q3 revenue miss and lowered guidance.

Expected impact

likely pressure as the market prices in the guidance cut and revenue miss

Evidence & confidence

Analyst downgrade with lower target and weak Q3 results typically trigger sell‑offs in small‑cap stocks.

Market effects

May weigh on other neurostimulation device makers as guidance concerns spread.

Limited to US small‑cap biotech sector.

Low; impact confined to NPCE and its niche sector.

Counterpoint

Some investors may see the lower target as an entry point if they believe clinical catalysts will materialize.

Key entities

  • KeyBanc

    Research firm that lowered the price target.

Related articles

$NPCEHigh

Why is NeuroPace stock plummeting 40% today?

NeuroPace (NPCE) stock fell 38.3% to $7.42 after reporting Q3 2026 revenue of $23.1M, missing estimates of $27.1M. The company cut its full-year 2026 revenue outlook to $91–92M from $99.5–101.5M, citing sales force disruptions. Leerink downgraded NPCE to Market Perform with a $7 target, while KeyBanc reduced its target to $14. Insider selling and a rate-sensitive macro environment added to the decline.

$NPCEMed

NeuroPace (NPCE) Q3 2026 Earnings Call Transcript

NeuroPace reported Q3 2026 revenue of $23.1M, missing expectations. CEO Joel Becker attributed the shortfall to transient issues, including account-specific operational challenges and sales team transitions. The company revised full-year revenue guidance to $91M-$92M and expects 15% core RNS revenue growth in 2027, accelerating to 20% by year-end. CMS increased the hospital outpatient payment rate for RNS replacement procedures by 11% for 2027.

$NPCEMed

What NeuroPace (NPCE) Said on Its Q3 Earnings Call

NeuroPace (NPCE) reduced its 2026 revenue guidance to $91M-$92M from $99.5M-$101.5M, citing delays at large accounts. Q4 procedure volumes show recovery signs. Adjusted gross margin forecast raised to 83%-83.5%, while operating expenses lowered to $85M-$86M. 2027 RNS revenue growth expected at 15%. FDA submissions for IGE and Remote Care feature are planned.

$NPCEMed

NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance

NeuroPace Inc (NPCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth Revises full year 2026 revenue guidance to $91 million to $92 million; focused on i